Clinical Myopia Control Trials and Instrumentation Report

James S. Wolffsohn, FCOptom, PhD, IMI Advisory Board

Ophthalmic Research Group, Aston University, Birmingham, United Kingdom

Committee members:
  • Dr. David Berntsen
  • Dr. Alexandra Benavente
  • Dr. Takohiro Hiraoka
  • Dr. Scott Read
  • Dr. David Atchison
  • Dr. Takashi Fujikado
  • Dr. Hetal Buckhurst
  • Dr. Pete Kolbaum
  • Dr. Arthur Bradley
  • Dr. Debbie Jones
  • Dr. Hidemasa Torii
  • Dr. Michael Collins
  • Dr. Nicola Logan
  • Dr. Linda Lundstrom
  • Masakazu Hirota

These findings and consensus from the International Myopia Institute members led to final recommendations to inform future instrumentation development and to guide clinical trial protocols.

Myopia has been predicted to affect approximately 50% of the world’s population based on trending myopia prevalence figures. Critical to minimizing the associated adverse visual consequences of complicating ocular pathologies are interventions to prevent or delay the onset of myopia, slow its progression, and to address the problem of mechanical instability of highly myopic eyes.

Although treatment approaches are growing in number, evidence of treatment efficacy is variable. This article reviews research behind such interventions under four categories: optical, pharmacological, environmental (behavioral), and surgical. In summarizing the evidence of efficacy, results from randomized controlled trials have been given most weight, although such data are very limited for some treatments.

The overall conclusion of this review is that there are multiple avenues for intervention worthy of exploration in all categories, although in the case of optical, pharmacological, and behavioral interventions for preventing or slowing progression of myopia, treatment efficacy at an individual level appears quite variable, with no one treatment being 100% effective in all patients.

Further research is critical to understanding the factors underlying such variability and underlying mechanisms, to guide recommendations for combined treatments. There is also room for research into novel treatment options.

Keywords: myopia control, optical, pharmacological, behavioral, surgical

Translated versions of IMI clinical summaries are available at myopiainstitute.org

The publication costs of the International Myopia Institute reports were supported by donations from BHVI, Carl Zeiss Vision, CooperVision, Essilor, Alcon, and Vision Impact Institute.

Share this article

Share on facebook
Share on google
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email

Copyright © Brien Holden Vision Institute (ABN 49 081 303 282) Brien Holden Vision Institute Foundation (ABN 86 081 872 586). All Rights Reserved.

Our site uses cookies. By continuing to use this website, you agree to their use. For more details, please check our Privacy Policy.